TSC is characterized by broad phenotypic heterogeneity, suggesting that other events beyond TSC1/TSC2 biallelic loss may act as disease modifiers and susceptibility loci for tumor development (Henske et al., 2016; Martin et al., 2017). This evidence concerns the gene TSC2 and neoplasm.